The Papillary Renal Cell Carcinoma drugs in development market research report provides comprehensive information on the therapeutics under development for Papillary Renal Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Papillary Renal Cell Carcinoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Papillary Renal Cell Carcinoma and features dormant and discontinued products.
GlobalData tracks 16 drugs in development for Papillary Renal Cell Carcinoma by 11 companies/universities/institutes. The top development phase for Papillary Renal Cell Carcinoma is phase ii with ten drugs in that stage. The Papillary Renal Cell Carcinoma pipeline has 16 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Papillary Renal Cell Carcinoma pipeline products market are: Pfizer, AstraZeneca and Bristol-Myers Squibb.
The key targets in the Papillary Renal Cell Carcinoma pipeline products market include Hepatocyte Growth Factor Receptor, Cytotoxic T Lymphocyte Protein 4, and Programmed Cell Death Protein 1.
The key mechanisms of action in the Papillary Renal Cell Carcinoma pipeline product include Hepatocyte Growth Factor Receptor Inhibitor with five drugs in Phase III. The Papillary Renal Cell Carcinoma pipeline products include eight routes of administration with the top ROA being Intravenous and five key molecule types in the Papillary Renal Cell Carcinoma pipeline products market including Small Molecule, and Monoclonal Antibody.
Papillary Renal Cell Carcinoma overview
Papillary renal cell carcinoma (PRCC), a form of kidney cancer, originates in the tubes responsible for filtering waste from the blood. There are two subtypes: Type 1, more common and slow-growing, and type 2, aggressive and fast-growing. Symptoms may include blood in urine, pain, weight loss, fatigue, fever, or a palpable lump. Diagnosis involves imaging scans like CT, MRI, and ultrasound, and confirmation through biopsy. Treatment is personalized, often involving surgery to remove tumors, though options vary with disease progression. Radiation therapy targets tumor areas, and chemotherapy is considered when surgery is impractical or in cases of metastasis.
For a complete picture of Papillary Renal Cell Carcinoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
